Evidence map›Paper›PMID 28283766›Full record

ArticleClinical rheumatology2017

Autoantibodies to types I and IV collagen and heart valve disease in systemic lupus erythematosus/antiphospholipid syndrome.

José Pardos-Gea, Josefina Cortés-Hernández, Jesus Castro-Marrero, Eva Balada, José Ordi-Ros

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

José Pardos-GeaDepartment of Internal Medicine, Autoimmune Diseases Unit, Vall Hebrón University Hospital, Universidad Autonoma de Barcelona, Pg. Vall d'Hebrón 119-129, 08035, Barcelona, Spain. jpardosgea@yahoo.es.ORCID http://orcid.org/0000-0002-3725-6849
Josefina Cortés-HernándezDepartment of Internal Medicine, Autoimmune Diseases Unit, Vall Hebrón University Hospital, Universidad Autonoma de Barcelona, Pg. Vall d'Hebrón 119-129, 08035, Barcelona, Spain.
Jesus Castro-MarreroDepartment of Internal Medicine, Autoimmune Diseases Unit, Vall Hebrón University Hospital, Universidad Autonoma de Barcelona, Pg. Vall d'Hebrón 119-129, 08035, Barcelona, Spain.
Eva BaladaDepartment of Internal Medicine, Autoimmune Diseases Unit, Vall Hebrón University Hospital, Universidad Autonoma de Barcelona, Pg. Vall d'Hebrón 119-129, 08035, Barcelona, Spain.
José Ordi-RosDepartment of Internal Medicine, Autoimmune Diseases Unit, Vall Hebrón University Hospital, Universidad Autonoma de Barcelona, Pg. Vall d'Hebrón 119-129, 08035, Barcelona, Spain.
Hebron University · PS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction/objectives autoantibodies to types I and IV collagen have been described in rheumatic fever and infective endocarditis. We tried to elucidate if an autoimmune response against collagens I and IV exists, associated with heart valve disease in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). A cohort of 172 patients with SLE (n = 79), primary APS (PAPS, n = 83), and secondary APS (n = 10) were assessed for valvulopathy by transthoracic echocardiograms. Autoantibodies to types I and IV collagen were assessed in patients and 50 controls, setting autoantibody positivity at two standard deviations above the mean antibody level of controls. Positive anticollagen IV antibody rate was significantly higher in SLE patients (17.7%) in respect to the rest of groups (PAPS 2.4%, controls 2%; P = 0.001). Percentage of positive autoantibodies to collagen I was similar in SLE and APS cohort of patients with and without valvular disease (48.4 vs 51.6%, respectively; P = 0.45). Percentage of positive autoantibodies to collagen IV was increased but not significantly in SLE and APS cohort of patients with respect to those without valvular disease (62.5 vs 37.5%, respectively; P = 0.08). Mean (standard deviation) levels of positive anticollagen I and IV antibodies did not differ between patients with and without valvular disease (85.6 ± 55 vs 81 ± 85 U/ml, respectively; P = 0.86 for anticollagen I) (0.05 ± 0.02 vs 0.12 ± 0.16 U/ml, respectively; P = 0.34 for anticollagen IV). Our data indicate a lack of association of autoantibodies to types I and IV collagen with heart valve disease in SLE and APS.

Indexed as

AdultAgedAntiphospholipid SyndromeAutoantibodiesCase-Control StudiesCollagen Type ICollagen Type IVFemaleHeart Valve DiseasesHumansLupus Erythematosus, SystemicMaleMiddle AgedAutoantibodiesCollagen Type ICollagen Type IVAntiphospholipidCollagen autoantibodiesLupusType I collagenType IV collagenValve heart disease

Identifiers

PMID28283766
OpenAlexW2593123296

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.